Literature DB >> 15665728

Effects of manganese superoxide dismutase nebulization on pulmonary function in an ovine model of acute lung injury.

Marc O Maybauer1, Yuji Kikuchi, Martin Westphal, Dirk M Maybauer, Kazuya Nishida, Lillian D Traber, Beena B Westphal-Varghese, Naoki Morita, Perenlei Enkhbaatar, David N Herndon, Daniel L Traber.   

Abstract

Smoke inhalation injury is a major cause of morbidity and mortality in thermally injured individuals. There is evidence of increased oxygen free radical activity, e.g., superoxide, in association with smoke inhalation injury. Because superoxide dismutase converts the reactive superoxide radical to peroxide, we hypothesized that nebulization of manganese superoxide dismutase (Mn-SOD) into the airway might attenuate pulmonary dysfunction secondary to smoke inhalation injury. The present study was designed as a prospective, controlled, and randomized laboratory experiment to determine the effects of aerosolized Mn-SOD on lung fluid balance, as indexed by changes in pulmonary microvascular permeability, lung lymph flow (Q(L)), and gas exchange in an established and clinically relevant ovine model of smoke inhalation injury. Fifteen female Merino sheep were chronically instrumented with a femoral arterial, a Swan-Ganz, and a left atrial catheter. In addition, the right caudal mediastinal lymph node was cannulated to measure Q(L) (mL.h(-1)). Pneumatic occluders were placed around the right pulmonary veins for the determination of the reflection coefficient (sigma). After 7 days of recovery, sheep were randomly allocated to (a) an untreated control group (4 groups of 12 breaths of cotton smoke), (b) an injured group treated with nebulized Mn-SOD (5 mg/kg), and (c) an injured group that received only the vehicle (nebulized saline). Nebulization was performed 1 h and 12 h after smoke inhalation. Mn-SOD nebulization attenuated the increase in both filtration coefficient and sigma and significantly decreased lung tissue conjugated dienes. However, there were no differences in Q(L), PaO2/FiO2 ratio, and bloodless lung wet/dry weight ratio between groups. Although Mn-SOD nebulization attenuated the loss of protein, it failed to improve lung edema and pulmonary gas exchange, thereby limiting its clinical use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665728     DOI: 10.1097/01.shk.0000150777.39484.b0

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  The peroxynitrite catalyst WW-85 improves microcirculation in ovine smoke inhalation injury and septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Andrew L Salzman; David N Herndon; Daniel L Traber
Journal:  Burns       Date:  2011-02-22       Impact factor: 2.744

2.  The peroxynitrite catalyst WW-85 improves pulmonary function in ovine septic shock.

Authors:  Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Robert A Cox; Martin Westphal; Levente Kiss; Eszter M Horvath; Lillian D Traber; Hal K Hawkins; Andrew L Salzman; Garry J Southan; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

Review 3.  Optimal management of the critically ill: anaesthesia, monitoring, data capture, and point-of-care technological practices in ovine models of critical care.

Authors:  Saul Chemonges; Kiran Shekar; John-Paul Tung; Kimble R Dunster; Sara Diab; David Platts; Ryan P Watts; Shaun D Gregory; Samuel Foley; Gabriela Simonova; Charles McDonald; Rylan Hayes; Judith Bellpart; Daniel Timms; Michelle Chew; Yoke L Fung; Michael Toon; Marc O Maybauer; John F Fraser
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

4.  Pharmaco-management of inhalation injuries for burn survivors.

Authors:  Anthony C Bartley; Dale W Edgar; Fiona M Wood
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 5.  Emerging therapies for smoke inhalation injury: a review.

Authors:  Alexandra Mercel; Nick D Tsihlis; Rob Maile; Melina R Kibbe
Journal:  J Transl Med       Date:  2020-03-30       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.